A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

  • STATUS
    Recruiting
  • End date
    Nov 27, 2022
  • participants needed
    82
  • sponsor
    Epizyme, Inc.
Updated on 26 May 2021
Investigator
Harry Miao, MD, PhD
Primary Contact
Children's National Medical Center (5.4 mi away) Contact
+35 other location

Summary

This is a Phase I, open-label, dose escalation and dose expansion study with BID (suspension) and TID (tablet) oral dose of tazemetostat. Subjects will be screened for eligibility within 14 days of the planned first dose of tazemetostat. A treatment cycle will be 28 days. Response assessment will be evaluated after 8 weeks of treatment and subsequently every 8 weeks while on study.

The study has two parts: Dose Escalation and Dose Expansion.

Dose escalation for subjects with the following relapsed/refractory malignancies:

  • Rhabdoid tumors:
  • Atypical teratoid rhabdoid tumor (ATRT)
  • Malignant rhabdoid tumor (MRT)
  • Rhabdoid tumor of kidney (RTK)
  • Selected tumors with rhabdoid features
  • INI1-negative tumors:
  • Epithelioid sarcoma
  • Epithelioid malignant peripheral nerve sheath tumor
  • Extraskeletal myxoid chondrosarcoma
  • Myoepithelial carcinoma
  • Renal medullary carcinoma
  • Other INI1-negative malignant tumors (e.g., dedifferentiated chordoma) (with Sponsor approval)
  • Synovial Sarcoma with a SS18-SSX rearrangement Dose Escalation cohorts are closed to enrollment.

Dose Expansion at the MTD or the RP2D

  • Cohort 1 - ATRT (closed to enrollment)
  • Cohort 2 - MRT/RTK/selected tumors with rhabdoid features (closed to enrollment)
  • Cohort 3 - INI-negative tumors:
  • Epithelioid sarcoma
  • Epithelioid malignant peripheral nerve sheath tumor
  • Extraskeletal myxoid chondrosarcoma
  • Myoepithelial carcinoma
  • Renal medullary carcinoma
  • Chordoma (poorly differentiated or de-differentiated)
  • Other INI1-negative malignant tumors (e.g., dedifferentiated chordoma) with Sponsor approval
  • Cohort 4 - Tumor types eligible for Cohorts 1 through 3 or synovial sarcoma with SS18-SSX rearrangement (closed to enrollment)

Details
Condition Rhabdoid Tumor, synovial sarcoma, Malignant Rhabdoid Tumor of Ovary, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors, INI1-negative Tumors
Treatment Tazemetostat
Clinical Study IdentifierNCT02601937
SponsorEpizyme, Inc.
Last Modified on26 May 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note